- Home
- CRIS vs PASG Comparison
CRIS vs PASG Comparison
Compare CRIS & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRIS | PASG |
|---|---|---|
| Founded | 2000 | 2017 |
| Country | United States | United States |
| Employees | N/A | 27 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.6M | 19.2M |
| IPO Year | 2000 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CRIS | PASG |
|---|---|---|
| Price | $4.63 | $4.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $17.00 | $14.00 |
| AVG Volume (30 Days) | ★ 7.6M | 93.8K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.57 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,898,000.00 | N/A |
| Revenue This Year | $27.10 | N/A |
| Revenue Next Year | $67.74 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 31.50 | N/A |
| 52 Week Low | $0.18 | $3.29 |
| 52 Week High | $6.74 | $20.00 |
Technical Indicators
Market Signals| Indicator | CRIS | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 73.85 | 47.04 |
| Support Level | $0.75 | $3.94 |
| Resistance Level | $6.74 | $5.06 |
| Average True Range (ATR) | 0.44 | 0.48 |
| MACD | 0.30 | -0.00 |
| Stochastic Oscillator | 66.77 | 88.14 |
Price Performance
Historical ComparisonAbout CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About PASG Passage Bio Inc.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.